Phase 2, open-label extension (OLE) study of revusiran, an investigational RNAi therapeutic for the treatment of patients with transthyretin cardiac amyloidosis

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Orphanet J Rare Dis
Prif Awduron: Gillmore, Julian D, Falk, Rodney H, Maurer, Mathew S, Hanna, Mazen, Karsten, Verena, Vest, John, Gollob, Jared, Hawkins, Philip N
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: BioMed Central 2015
Pynciau:
Oral Presentation
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4641992/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1750-1172-10-S1-O21
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg